tradingkey.logo
tradingkey.logo
Suchen

ARS Pharmaceuticals Inc

SPRY
Zur Watchlist hinzufügen
8.560USD
+0.620+7.81%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
850.01MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über ARS Pharmaceuticals Inc Unternehmen

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

ARS Pharmaceuticals Inc Informationen

BörsenkürzelSPRY
Name des UnternehmensARS Pharmaceuticals Inc
IPO-datumDec 04, 2020
CEOLowenthal (Richard E)
Anzahl der mitarbeiter155
WertpapierartOrdinary Share
GeschäftsjahresendeDec 04
Addresse11682 El Camino Real, Suite 300
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92130
Telefon18587719307
Websitehttps://ars-pharma.com/
BörsenkürzelSPRY
IPO-datumDec 04, 2020
CEOLowenthal (Richard E)

Führungskräfte von ARS Pharmaceuticals Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Saqib Islam, J.D.
Mr. Saqib Islam, J.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric Karas
Mr. Eric Karas
Chief Commercial Officer
Chief Commercial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von ARS Pharmaceuticals Inc?

Die fünf größten Anteilseigner von ARS Pharmaceuticals Inc sind: Mr. Richard E. Lowenthal

Wie viele Institutionen halten Anteile an ARS Pharmaceuticals Inc (SPRY)?

Mit Stand vom 2026Q1 halten 412 Institutionen Anteile an ARS Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 96.79M, was 97.47% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -8902286.00 gestiegen.